{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T02:10:23Z","timestamp":1697508623165},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":120,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,8,22]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>: The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of <jats:italic>Helicobacter pylori<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>: To evaluate the efficacy and safety of ecabet sodium\u2010based eradication of <jats:italic>H. pylori<\/jats:italic> infection, compared with a lansoprazole\u2010based regimen, in a randomized multicentre study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Subjects and methods<\/jats:title><jats:p>: A total of 120 <jats:italic>H. pylori<\/jats:italic>\u2010positive patients were assigned to one of two treatment regimens for 2\u2003weeks: ecabet sodium 1\u2003g b.d., amoxicillin 500\u2003mg t.d.s. and clarithromycin 400\u2003mg b.d. (EAC: 60 patients); or lansoprazole 30\u2003mg (o.m.) with the same antimicrobial agents (LAC: 60 patients). Cure of infection was assessed by a <jats:sup>13<\/jats:sup>C\u2010urea breath test 1\u2003month after completion of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>: One patient in the EAC group and two in the LAC group did not complete therapy because of an adverse event, and three did not undergo the <jats:sup>13<\/jats:sup>C\u2010urea breath test. Cure rates for the intention\u2010to\u2010treat, all\u2010patients\u2010treated and per protocol analysis in the EAC group were 85%, 86% and 88%, respectively, whereas those in the LAC group were 85%, 88% and 91%. There were no significant differences in cure rate or adverse events between the two regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>: Ecabet sodium in combination with amoxicillin and clarithromycin is as effective as lansoprazole\u2010based eradication therapy for <jats:italic>H. pylori<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01022.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:56Z","timestamp":1047354296000},"page":"1187-1191","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of ecabet sodium for <i>Helicobacter pylori<\/i> eradication triple therapy in comparison with a lansoprazole\u2010based regimen"],"prefix":"10.1111","volume":"15","author":[{"given":"K.","family":"Adachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Niigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91816-6"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280512"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199110173251603"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(93)90233-7"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-2-199907200-00003"},{"key":"e_1_2_7_7_2","first-page":"S43","article-title":"New developments in Helicobacter pylori eradication therapy","volume":"32","author":"Pounder RE","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)80027-3"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.62.169"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.18.850"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-2999(97)01622-1"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1295"},{"key":"e_1_2_7_13_2","first-page":"525","article-title":"Bactericidal effect of ecabet sodium on clarithromycin\u2010 and metronidazole\u2010resistant clinical isolates of Helicobacter pylori","volume":"50","author":"Shibata K","year":"1997","journal-title":"Jpn J Antibiot"},{"key":"e_1_2_7_14_2","first-page":"59","article-title":"Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients","volume":"31","author":"Shimoyama T","year":"1996","journal-title":"J Gastroenterol"},{"key":"e_1_2_7_15_2","first-page":"A122","article-title":"Usefulness of ecabet sodium in the H. pylori eradication therapy with relation to side effects","volume":"112","author":"Furuta T","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00324.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00852.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00791.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199800001-00024"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb1978.14.547"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.51.65"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018885005109"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.52.631"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02934107"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506002-00036"},{"key":"e_1_2_7_26_2","first-page":"A190","article-title":"High eradication rate of Helicobacter pylori with lansoprazole\u2003+\u2003amoxicillin\u2003+ ecabet sodium: new triple therapy with novel mucosal protective agent for the treatment of peptic ulcer","volume":"110","author":"Matsukura N","year":"1996","journal-title":"Gastroenterology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01022.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01022.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01022.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:41:32Z","timestamp":1697506892000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01022.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8,22]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8,22]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01022.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01022.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8,22]]}}}